HYPR: Hyperfine EV/EBITDA Multiple

Corporate emblem and logo of Hyperfine (HYPR)

Hyperfine, Inc. (HYPR) ensures the stability of mobile MRI production through the diversification of component supplies, which supports profitability. The company has created a unique compact scanner for point-of-care diagnostics, expanding the accessibility of healthcare. This daily price chart illustrates an EV/EBITDA of 0.00, while demand for Swoop systems in hospitals continues to grow rapidly.

Hyperfine Medical - HYPR Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for hyperfine.io (HYPR)

- stock price and consensus target price:
Stock Quotes Hyperfine Corp|HYPR - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Hyperfine Medical|HYPR - Company Buyout Price
- issuer book value statistics:
Book Value per Share Hyperfine|HYPR - Company Net Assets|Market Cap to Net Assets Ratio hyperfine.io|HYPR - Aggregate Asset Value
- company liabilities and liquidity data:
Debt to Equity Hyperfine, Inc.|HYPR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Hyperfine|HYPR - Company Cumulative Debt|Debts to Book Capitalization Hyperfine Medical|HYPR - Company Long-Term Indebtedness|Company Short-Term Debts Hyperfine|Quick Ratio hyperfine.io
- financial results and valuation multiples details:
HYPR - Net Income|Projected Future Earnings Hyperfine, Inc.|HYPR - P/E Multiple|Future Price to Earnings Hyperfine, Inc.|HYPR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Hyperfine Medical|HYPR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Hyperfine|HYPR - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months hyperfine.io|HYPR - Net earnings per share change in current year|Expected earnings per share growth for next year Hyperfine, Inc.
Initial company analysis:Hyperfine Corp HYPR
Original product of hyperfine.io

The EV/EBITDA business valuation trend reflects the market value of Hyperfine, Inc. (HYPR) while accounting for debt load relative to operating profit. This metric compares the total cost of acquiring the asset with its ability to generate cash flow before taxes, depreciation, and amortization. The formula's sensitivity allows for the real-time tracking of how the scaling of the Swoop system and the implementation of AI algorithms impact capitalization. A stable trend confirms the company's fundamental resilience during periods of market volatility.

Competitor analysis for Hyperfine, Inc.

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Seer Bio (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR Corporation FONR|Daxor Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)